Two versus three-class antiretroviral therapy in antiretroviral-naive patients in different time periods of the HAART era [6]

AIDS

Volumn 21, Issue 4, 2007, Pages 537-538

  Taffé, Patrick ^a   Bucher, Heiner C ^b,c   Flepp, Markus ^d   Battegay, Manuel ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; VIRAL LOAD;

EID: 33847080449     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32803277d9     Document Type: Letter

References (10)

1. Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 2006; 20:1141-1150.
2. Collett D. Modelling survival data in medical research. 2nd ed. Boca Raton, FL: Chapman and Hall/CRC; 2003.
3. Diggle PJ, Heagerty P, Liang KY, Zeger SL. Analysis of longitudinal data. 2nd ed. Oxford: Oxford University Press; 2002.
4. Greenland S. Partial and marginal matching in case-control studies (invited paper). In: Modern statistical methods in chronic disease epidemiology. Edited by Moolgavkar SH, Prentice RL. New York: Wiley; 1986. pp. 35-49.
5. Lyles RH, Lyles CM, Taylor D. Random regression models for human immunodeficiency ribonucleic acid data subject to left censoring and informative drop-outs. Appl Statist 2000; 49: 485-497.
6. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA 2006; 296:827-843.
7. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006; 6:280-287.
8. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to < 500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41:361-372.
9. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
10. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378-384.